Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teriparatide oral - Entera Bio

Drug Profile

Teriparatide oral - Entera Bio

Alternative Names: EB-612; EB-613; EBP-05; EP-101 - Entera Bio; hPTH(1-34); Oral hPTH(1-34); Oral PTH (1-34); oral PTH(1-34), teriparatide; Parathyroid hormone oral - Entera Bio; Parathyroid hormone-1-34 - Entera Bio; PTH oral - Entera Bio; PTH-1-34 - Entera Bio

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Entera Bio
  • Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Parathyroid hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypoparathyroidism; Osteoporosis
  • Preclinical Non-union fracture

Most Recent Events

  • 11 Mar 2024 Entera Bio plans a phase II trial for Fracture due to intense sport and military stress injuries (PO)
  • 03 Jan 2024 Entera Bio plans a registrational pivotal phase III trial for Osteoporosis in USA (PO) in 2024
  • 29 Nov 2023 Interim pharmacodynamics and pharmacokinetics data from a phase I trial in Hypoparathyroidism (In volunteers) released by Entera Bio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top